Ankylosing Spondylitis Clinical Trial
Official title:
Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study
This study will explore how genes-units of heredity-may influence the severity of ankylosing
spondylitis. It will examine whether some genes may cause people with ankylosing spondylitis
to have more rapid fusion of the bones of the spine, more difficulty performing daily
activities, or be more likely to need joint surgery.
Patients who developed ankylosing spondylitis after age 16 and have had the disease for 20
years or more may be eligible for this study. The onset of disease is dated to the first
appearance of symptoms of inflammatory low back pain or restricted spinal motion. Patients
with a spondyloarthropathy other than AS may not enroll.
Participants will complete a brief medical history and physical exam. They will fill out a
30-minute questionnaire that includes questions on demographics (such as age, ethnicity,
marital status, etc.), medication history, work history, hip surgeries, and assessment of
functional disability. Fifty milliliters (about 3-1/3 tablespoons) of blood will be drawn for
gene testing, and X-rays will be taken of the pelvis, lower back, and neck, if recent X-rays
(within 1 year) are not available. Women of childbearing age will have a urine pregnancy test
before having X-rays.
The susceptibility to ankylosing spondylitis (AS) is largely genetically determined. Recent
studies suggest that the severity of AS is also influenced to a large extent by genetic
factors. The goal of this study is to identify genes that influence the severity of AS. We
hypothesize that genetic markers of susceptibility, including human leukocyte antigen (HLA)
polymorphisms, are among the genes that also influence the severity of AS. Other genes that
could potentially influence the severity of AS include those that affect the severity of
joint inflammation and those that influence bone formation.
In this cross-sectional study, we will test the association of HLA markers and polymorphisms
in several genes involved in the regulation of inflammation and bone formation with the
severity of AS. Approximately 500 patients will be enrolled. Each patient will have had AS
for at least 20 years. Measures of AS severity will be the extent of spinal fusion as
measured radiographically, functional disability, time to permanent work disability, and need
for total hip arthroplasty.
Identifying genetic markers that are associated with differences in the severity of AS will
greatly enhance our understanding of the pathogenesis of this disease by suggesting
mechanisms and pathways involved in the development of long-term damage. In a separate but
related protocol, we will assess genetic markers associated with persistent active
inflammation in patients with AS.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
| Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
| Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
| Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
| Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
| Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
| Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
| Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
| Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |